The combined phosphorylation of Mcl-1 leads to an increase release of caspases and initiates degradation of AML cells similar to the targeted therapy antibody gemtuzumab ozogamicin (GO (CMA-676); Wyeth Laboratories, Mylotarg®, Philadelphia, PA, USA) [101]. The gene discussed is MCL1; the disease is acute myeloid leukemia.